Angiogenesis Antibodies

Cat. No.

AT0855

Anti-VEGFR2/KDR/CD309 Antibody (AT001)

The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized monoclonal antibody, produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target VEGFR2/KDR/CD309. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, and exhibits a molecular weight of approximately 145 kDa. For experimental control purposes, the Human IgG4 kappa Isotype Control is recommended. This product is essential for research focused on the biological pathways mediated by VEGFR2/KDR/CD309, including angiogenesis and vascular development, making it highly relevant in studies of cancer, cardiovascular diseases, and other angiogenesis-related disorders.

Cat. No.

AT0984

LY3022856

LY3022856 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Vascular Endothelial Growth Factor Receptor 3 (VEGFR3), also known as FLT4. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 146.18 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for use in research applications focusing on the role of VEGFR3 in angiogenesis and lymphangiogenesis.

Cat. No.

AT0993

CAS No.

1531589-13-5

Brolucizumab

Synonyms: DLX1008; ESBA 1008; RTH258

Brolucizumab (DLX1008) is a high-affinity single-chain anti-VEGF-A antibody fragment, demonstrating a dissociation constant (K_D) of 1.05 pM. This monoclonal antibody is engineered for precise targeting and inhibition of vascular endothelial growth factor A (VEGF-A), a key molecule involved in angiogenesis. Brolucizumab is utilized primarily in oncological research to study and inhibit tumor-induced blood vessel formation, offering potential insights into cancer therapy mechanisms.

Cat. No.

AT0996

CAS No.

1610010-57-5

Suvemcitug

Suvemcitug is a humanized IgG1κ monoclonal antibody that specifically targets vascular endothelial growth factor (VEGF). This antibody is derived from Oryctolagus cuniculus, commonly known as the African hare. It is designed for use in research applications focused on angiogenesis and vascular biology.

Cat. No.

AT1007

Anti-VEGFR1/FLT1 Antibody

The Anti-VEGFR1/FLT1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting VEGFR1/FLT1. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended. This product is pivotal in studies focusing on the modulation and function of VEGFR1/FLT1 in angiogenesis and vascular biology.

Cat. No.

AT1009

CAS No.

2867549-73-1

Micvotabart

Micvotabart is a human monoclonal antibody of the IgG1κ isotype that specifically targets fibronectin 1 (FN1). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT1046

CAS No.

2408661-40-3

Tarcocimab

Synonyms: OG1953

Tarcocimab (OG1953) is a humanized monoclonal antibody of the IgG1 subtype, specifically targeting VEGFA. This antibody is utilized in research focusing on retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD), offering a valuable tool for investigating the pathological mechanisms and potential therapeutic interventions for these ocular conditions.

Cat. No.

AT1115

CAS No.

216974-75-3

Bevacizumab (PBS)

Synonyms: Anti-Human VEGF; Humanized Antibody (PBS

Bevacizumab is a humanized IgG1 monoclonal antibody that exhibits high-affinity binding to all isoforms of vascular endothelial growth factor A (VEGF-A). This targeted binding inhibits the interaction of VEGF-A with its receptors, thereby modulating angiogenesis.

Cat. No.

AT1131

CAS No.

947687-13-0

Ramucirumab (anti-VEGFR)

Ramucirumab is a recombinant human IgG1 monoclonal antibody specifically designed to target and antagonize vascular endothelial growth factor receptor 2 (VEGFR-2). By binding to the extracellular domain of VEGFR-2, Ramucirumab effectively inhibits the interaction with its natural ligands, VEGF-A, VEGF-C, and VEGF-D. This blockade disrupts the downstream signaling pathways that promote angiogenesis, making Ramucirumab a potent angiogenesis inhibitor. It is primarily utilized in the clinical management of various solid tumors, leveraging its mechanism to impair tumor vascularization and growth.

Cat. No.

AT1192

Anti-PDGFC/VEGFE Antibody

Cat. No.

AT1218

CAS No.

2095504-49-5

Olinvacimab

Synonyms: TTAC-0001

Olinvacimab (TTAC-0001) is a fully human monoclonal antibody targeting VEGFR2, exhibiting potent antiangiogenic properties. This antibody binds specifically to the kinase insert domain receptor (KDR), a known alias for VEGFR2, with a high affinity characterized by a dissociation constant (Kd) of 0.23 nM. By inhibiting the vascular endothelial growth factor (VEGF) pathway, Olinvacimab effectively disrupts tumor angiogenesis. It is primarily utilized in research focused on investigating therapeutic approaches for recurrent glioblastoma and breast cancer.

Cat. No.

AT1223

CAS No.

1569263-06-4

Rinucumab

Synonyms: REGN 2176

Rinucumab (REGN 2176) is a monoclonal antibody designed to inhibit platelet-derived growth factor (PDGF), making it a valuable tool for research into neovascular age-related macular degeneration. This antibody specifically targets PDGF pathways, which are implicated in the pathological angiogenesis associated with this condition. Rinucumab (REGN 2176) is utilized primarily in studies aimed at understanding and potentially mitigating the progression of neovascular age-related macular degeneration.

Cat. No.

AT1227

CAS No.

1192578-27-0

Enoticumab

Synonyms: REGN421

Enoticumab (REGN421, SAR153192) is a monoclonal antibody of the IgG1κ subtype designed to specifically target human Delta-like ligand 4 (DLL4). DLL4 is an integral component of the Notch signaling pathway, which is known to influence a variety of cellular processes including the regulation of fatty acid uptake via non-transcriptional modulation of macropinocytosis-dependent mechanisms. This antibody has demonstrated significant efficacy in preclinical studies, particularly in models of ovarian cancer. Administration of Enoticumab at a dosage of 2.5 mg/kg once weekly led to tumor growth inhibition rates of 86% in subcutaneous TOV-112D and 83% in intraperitoneal A2780 human tumor xenograft models. These findings underscore its potential utility in therapeutic applications targeting DLL4-mediated pathways.

Cat. No.

AT1245

CAS No.

1243266-04-7

Tovetumab

Synonyms: MEDI-575

Tovetumab (MEDI-575) is a monoclonal antibody specifically targeting PDGFRα, designed to inhibit signal transduction pathways mediated by this receptor. This antibody is utilized primarily in the investigation of pathological conditions such as glioblastoma and non-small cell lung cancer (NSCLC), where PDGFRα plays a critical role in disease progression and cellular proliferation. Tovetumab offers a strategic tool for researchers studying the molecular mechanisms and therapeutic interventions related to these cancers.

Cat. No.

AT1253

Anti-PDGFB Antibody (MOR-8457)

Synonyms: MOR-8457

MOR-8457 is a monoclonal antibody specifically designed to target PDGF-BB, a critical factor implicated in the pathogenesis of liver fibrosis. This antibody is optimized for use in murine models to investigate the molecular mechanisms and potential therapeutic targets for liver fibrosis.

Cat. No.

AT1265

CAS No.

1024603-92-6

Icrucumab

Synonyms: Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1

Icrucumab (IMC-18F1) is a human IgG1 monoclonal antibody that targets VEGFR-1 (FLT1). This antibody exhibits potential utility in the research of advanced solid tumors, providing a critical tool for investigating the role of VEGFR-1 in tumor angiogenesis and progression.

Cat. No.

AT1316

Anti-ANGPT2 Antibody

Cat. No.

AT1416

Anti-PDGFRB/CD140b Antibody (IMC-2C5)

Synonyms: IMC-2C5

IMC-2C5 is a fully human monoclonal antibody that acts as an antagonist to platelet-derived growth factor receptor beta (PDGFRβ). This antibody is designed to enhance antitumor activity and potentiate the effects of antiangiogenic agents across a diverse array of human cancers. Targeting PDGFRβ, IMC-2C5 has demonstrated efficacy in inhibiting tumor growth and angiogenesis, making it a valuable tool for cancer research and therapeutic development.

Cat. No.

AT1427

Anti-VEGF Antibody

Cat. No.

AT1458

CAS No.

216974-75-3

Bevacizumab

Synonyms: Anti-Human VEGF; Humanized Antibody

Bevacizumab is a humanized IgG1 monoclonal antibody designed to bind with high affinity to all isoforms of vascular endothelial growth factor A (VEGF-A). This specific interaction inhibits the biological activity of VEGF-A, which plays a critical role in angiogenesis and the promotion of tumor growth. Bevacizumab is utilized extensively in research focused on cancer therapy, particularly in studies exploring the mechanisms of angiogenesis inhibition in tumor progression.

Cat. No.

AT1464

Anti-TIE2/CD202b Antibody

Cat. No.

AT1465

CAS No.

1447814-75-6

Brontictuzumab

Synonyms: OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody

Brontictuzumab (OMP 52M51) is a monoclonal antibody designed to target and inhibit the Notch1 signaling pathway. This antibody specifically binds to the negative regulatory region of Notch1, a critical component in cell differentiation, proliferation, and apoptotic processes. By inhibiting this pathway, Brontictuzumab effectively impedes tumor cell proliferation, making it a valuable tool in the study of hematological malignancies such as leukemia and lymphoma. Its selective binding affinity and inhibitory action on Notch1 provide a focused approach for researchers investigating the pathological roles of Notch1 signaling in cancer.

Cat. No.

AT1479

CAS No.

1296818-77-3

Nesvacumab

Nesvacumab is a fully human monoclonal antibody of the immunoglobulin G1 (IgG1) class, designed to selectively target and neutralize the Tie2 receptor ligand Angiopoietin-2 (Ang2). It exhibits high binding affinity specifically for Ang2, without interacting with Angiopoietin-1 (Ang1). This specificity makes it an ideal candidate for research focused on vascular biology and diseases associated with Ang2-mediated signaling pathways.

Cat. No.

AT1542

CAS No.

2642578-92-3

Reflocibart

Reflocibart is a human IgG4 κ monoclonal antibody targeting VEGFB. For accurate experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Cat. No.

AT1545

CAS No.

1448221-05-3

Vanucizumab

Synonyms: Anti-Human VEGFA Recombinant Antibody; RO5520985

Vanucizumab is a pioneering bispecific IgG1-like monoclonal antibody designed to concurrently inhibit the interaction of vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2) with their respective receptors. This dual blockade mechanism endows vanucizumab with potent antiangiogenic and anticancer properties, making it an essential tool for research in tumor growth and metastasis inhibition.